88 related articles for article (PubMed ID: 31313121)
21. Cervical cancer screening by human papillomavirus testing followed by cytology triage--reply.
Feldman S
JAMA Intern Med; 2015 Jun; 175(6):1068-9. PubMed ID: 26030859
[No Abstract] [Full Text] [Related]
22. HPV Testing in Resource-Limited Settings: How Can We Reach the Next Level of Cervical Cancer Screening in Latin America and the Caribbean?
Randall TC; Salicrup LA; Luciani S; Trimble EL
Oncologist; 2015 Oct; 20(10):1101-4. PubMed ID: 26330459
[TBL] [Abstract][Full Text] [Related]
23. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program.
Machalek DA; Roberts JM; Garland SM; Thurloe J; Richards A; Chambers I; Sivertsen T; Farnsworth A
Med J Aust; 2019 Aug; 211(3):113-119. PubMed ID: 31168828
[TBL] [Abstract][Full Text] [Related]
24. Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe.
Fitzpatrick M; Pathipati MP; McCarty K; Rosenthal A; Katzenstein D; Chirenje ZM; Pinsky B
BMC Womens Health; 2020 Jul; 20(1):153. PubMed ID: 32711530
[TBL] [Abstract][Full Text] [Related]
25. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
Holt HK; Zhang L; Zhao FH; Hu SY; Zhao XL; Zhang X; Pan QJ; Zhang WH; Smith JS; Qiao YL
Int J Cancer; 2017 Feb; 140(3):544-554. PubMed ID: 27727464
[TBL] [Abstract][Full Text] [Related]
27. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.
Naber SK; de Kok IM; Matthijsse SM; van Ballegooijen M
Cancer Causes Control; 2016 Apr; 27(4):569-81. PubMed ID: 26970740
[TBL] [Abstract][Full Text] [Related]
28. Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.
Pimple SA; Mishra GA
Minerva Ginecol; 2019 Oct; 71(5):365-371. PubMed ID: 31698891
[TBL] [Abstract][Full Text] [Related]
29. The role of human papillomavirus testing in cervical cancer screening.
Morasse L; Davidov A; Castellanos MR
JAAPA; 2009 Nov; 22(11):20-3. PubMed ID: 19999172
[No Abstract] [Full Text] [Related]
30. Text messages to increase attendance to follow-up cervical cancer screening appointments among HPV-positive Tanzanian women (Connected2Care): study protocol for a randomised controlled trial.
Linde DS; Andersen MS; Mwaiselage JD; Manongi R; Kjaer SK; Rasch V
Trials; 2017 Nov; 18(1):555. PubMed ID: 29162148
[TBL] [Abstract][Full Text] [Related]
31. Role of HPV DNA testing in modern gynaecological practice.
Ronco G; Giorgi Rossi P
Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():107-118. PubMed ID: 28918099
[TBL] [Abstract][Full Text] [Related]
32. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
33. Public awareness and cervical cancer screening.
Davies P
Cytopathology; 2012 Jun; 23(3):143-5. PubMed ID: 22587553
[No Abstract] [Full Text] [Related]
34. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
35. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
36. Cervical cancer screening in Switzerland: time to rethink the guidelines.
Vassilakos P; Catarino R; Frey Tirri B; Petignat P
Swiss Med Wkly; 2015; 145():w14112. PubMed ID: 25664576
[No Abstract] [Full Text] [Related]
37. Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study.
Swanson M; Ibrahim S; Blat C; Oketch S; Olwanda E; Maloba M; Huchko MJ
BMC Womens Health; 2018 Jul; 18(1):116. PubMed ID: 29970063
[TBL] [Abstract][Full Text] [Related]
38. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
39. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.
Coldman AJ; Phillips N; van Niekerk D; Smith L; Krajden M; Cook D; Quinlan DJ; Ehlen T; Miller D; Stuart GC; Peacock S; Martin RE; Franco EL; Ogilvie G
J Obstet Gynaecol Can; 2015 May; 37(5):412-420. PubMed ID: 26168101
[TBL] [Abstract][Full Text] [Related]
40. Comparison of clinical performance of two high-throughput liquid bead microarray assays, GeneFinder and CareGENE, for cervical screening in the general population.
Moon JH; Jeong K; Kim K; Lee C; Jin MS; Ryu HS
Arch Virol; 2019 Nov; 164(11):2699-2706. PubMed ID: 31435867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
